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2005 to July. 2018. Adjuvant radiotherapy included external irradiation on
pelvic area and brachytherapy to vaginal stump. Hormonal therapy and
chemotherapy were administrated to some of the patients. Propensitymatched analysis (PSM) was used to eliminate group difference and
Kaplan-Meier survival analysis was done to calculate survival.
Results: 132 patients with resected Low-grade endometrial stromal sarcoma were included in the analysis. The median age was 43 years and
90.8% of patients was premenopausal. Stage I and II accounted for most
(76.0% and 19.4%, respectively), followed by stage III - IVA. Among all
patients, 103 patients underwent bilateral oophorectomy and 5 patients
underwent unilateral oophorectomy while the others preserved ovaries.
Hormonal therapy was prescribed to 60 (45.5%) patients. A total of 32
(24.2%) patients received postoperative radiotherapy (RT group), while
100 patients did not receive adjuvant radiotherapy (no RT group). The two
groups were comparable in age, tumor diameter, stage, menopausal status
et al. However, proportion of hormonal therapy (68.8% vs. 38.0%, P Z
0.002) and bilateral oophorectomy (90.6% vs. 74.0%, P Z 0.048) in the
RT group were significantly higher than those in the no RT group. The
median follow-up time was 40.5 months. 32 patients relapsed (24.2%,
including 22 cases limited to pelvic area, 6 cases relapsed in pelvic and
abdominal area, 2 cases relapsed in pelvic area and lungs, 1 case relapsed
in pelvic, abdominal area and lungs, 1 case to lungs) and 1 patient (0.8%)
died during follow-up. For all patients, 1-year disease-free survival (DFS)
was 90.6%, 3 yrs DFS was 79.0%, 5 yrs DFS was 71.2%. Univariate
analysis showed that radiotherapy, menopausal status and bilateral oophorectomy significantly prolonged DFS. Postoperative radiotherapy
reduced recurrence rate (12.5% (4/32) vs. 27.0% (27/100)). We then did a
propensity-matched analysis to eliminate unbalanced factors in RT group
and no RT group. A total of 64 patients were matched according to
menopausal status, bilateral oophorectomy and hormonal therapy. KaplanMeier analysis showed significant improved DFS in RT group compared to
no RT group (median DFS: not reached vs. 81monthes, p Z 0.004). In
terms of toxicity, there was no radiotherapy induced grade III-IV toxicity.
Conclusion: In patients with Low-grade endometrial stromal sarcoma after
radical resection, postoperative radiotherapy showed significant improvement on DFS which emphasized importance of radiotherapy in ESS.
Author Disclosure: W. Wang: None. X. Hou: None. K. Hu: None. F.
Zhang: None.

with stage IB and 77 (17%) with stage II. Group A consisted of 354 (77%)
patients, and group B had 106 (23%). The median TIs from hysterectomy
to ART were 6 weeks and 10 weeks for groups A and B, respectively.
There was no statistically significant difference between the groups in
terms of baseline demographic and disease characteristics including age,
race, grade, FIGO stage, extent of myometrial invasion, presence of
lymphovascular space invasion and radiation treatment modality. A total of
52 patients experienced recurrences. Patients in group A (vs. group B)
experienced significantly less recurrences overall (9% vs. 18%; p Z 0.01).
Rate of vaginal recurrence was significantly lower in group A (9% vs.
42%, p Z 0.01). Univariate analysis showed that having RT 8 weeks was
associated with significantly improved 5-year RFS rate, which was 89%
and 80% for groups A and B (p Z 0.04), respectively. The rates of 5-year
OS (86% vs. 85% for groups A and B, respectively) and 5-year DSS (93%
vs. 93% for groups A and B, respectively) were similar. In addition,
multivariate analysis showed a statistical trend for improved 5-year RFS
when receiving RT 8 weeks (p Z 0.07).
Conclusion: Our study suggests that delaying adjuvant radiation treatment
beyond 8 weeks post-hysterectomy is associated with significantly more
cancer recurrences for women with early-stage endometrial cancer.
Author Disclosure: S. Zhu: None. R. Khalil: None. O. Altairy: None. C.
Burmeister: None. I. Dimitrova: None. M.A. Elshaikh: None.
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Hysterectomy and Initiation of Adjuvant Radiation
Treatment in Women With Early-Stage Endometrial
Carcinoma
S. Zhu,1 R. Khalil,1 O. Altairy,1 C. Burmeister,2 I. Dimitrova,3
and M.A. Elshaikh1; 1Department of Radiation Oncology, Henry Ford
Cancer Institute, Detroit, MI, 2Department of Public Health Science,
Henry Ford Cancer Institute, Detroit, MI, 3Department of Gynecologic
Oncology, Henry Ford Cancer Institute, Detroit, MI
Purpose/Objective(s): Adjuvant radiation therapy (ART) is indicated for
women with endometrial carcinoma (EC) who are at high risk for recurrence. However, due to various reasons, some patients do not receive ART
in a timely manner. In this study, we evaluated the prognostic impact of the
time interval (TI) between hysterectomy and starting date of ART.
Materials/Methods: After institutional review board approval, we queried
our prospectively-maintained institutional database for women with uterine endometrioid EC of 2009 FIGO stages I-II who received ART without
chemotherapy after surgical staging. The patients were classified into two
groups, based on whether they received ART 8 weeks (group A) or >8
weeks (group B) after hysterectomy. We then compared the two groups
with regards to the following survival endpoints: recurrence-free survival
(RFS), disease-specific survival (DSS) and overall survival (OS). Univariate and multivariate analyses were also performed.
Results: A total of 460 patients were identified. Median follow-up duration
was 70.5 months. The median age for the entire cohort was 66.0 years. The
cohort consisted of 176 patients with FIGO stage IA (38%), 207 (45%)
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Dose-volume Parameters of Pelvic Functional Bone Marrows
Predict Acute Hematological Toxicities during IntensityModulated Radiotherapy Concurrent With or Without
Cisplatin for Cervical/ Endometrial Cancer: A Prospective II
Study
H. Chen,1 W. Deng,1 Q. Zhong,1 Y. Liu,1 X. Ruan,1 Z. Yu,1 J. Chen,1
D. Rao,1 and L. Xiao2; 1Jiangmen Central Hospital, Jiangmen,
Guangdong Province, China, 2Jiangmen Central Hospital, Jiangmen,
Guangdong Province, China
Purpose/Objective(s): Pelvic functional bone marrow (FBM) has active
hematopoietic capacity. Our hypothesis is that dose-volume parameters of
pelvic FBM may predict the risk of hematological toxicity (HT) during
chemoradiotherapy for cervical and endometrial cancer.
Materials/Methods: In this prospective phase II trial, 51 patients with
cervical cancer and 13 patients with endometrial cancer were recruited
from January 2017 to January 2020. All patients were treated with 5-7
fields IMRT. 44 patients were postoperative radiotherapy (45-50.4Gy/2528 Fractions), 1 of them was concurrently boosted to 60 Gy/28 Fractions
for parametrial positive margin, 3 of them were boosted with brachytherapy for vaginal positive margin. 20 patients were radical radiotherapy
(50.4 Gy/28 fractions plus brachytherapy), 14 of them were concurrently
boosted to 60 Gy/28 Fractions for pelvic positive lymph nodes. FBM1 and
FBM2 were outlined in the condition of bone window. All patients
received concurrent median 4 cycles (0-7 cycles) of cisplatin (40 mg/m2
qw). The blood routine was reviewed weekly during chemoradiotherapy.
The HT was evaluated according to the CTC4.0 criteria. The single and
multi-factors methods were used to analyze the relationship between grade
3-4 HT and dose-volume parameters of FBM1, FBM2.
Results: The incidence of grade 3-4 leukopenia, neutropenia, thrombocytopenia, and hemoglobin a during chemoradiotherapy was 32.8%,
15.6%, 14.1%, and 20.3%, respectively, and the median occurrence time
was 42th, 40th, 36th, and 42th day, respectively. Multivariate regression
analysis showed Dmax of FBM1 was significantly associated with grade 34 leukopenia (OR Z 1.483 95% CI 1.182 w1.862), and V50 of FBM1 was
significantly associated with grade 3-4 neutropenia (OR Z 1.322 95%CI
1.014w1.724). Compared with patients without lymph node boost, patients with boost had a significantly higher risk of grade 3-4 neutropenia
(40% vs. 8.2%, P Z 0.008) and thrombocytopenia, (46.7% vs. 4.1%,
P<0.001). Patients treated with radical radiotherapy had significantly
higher risk of grade 3-4 hemoglobin a than those with postoperative
radiotherapy (80% vs. 25 %, P <0.001). The significant risk factors for
synchronous more than one blood cell type grade 3-4 suppression (namely

